Revolution Medicines (RVMDW) Cash from Operations (2019 - 2026)
Revolution Medicines (RVMDW) posted quarterly Cash from Operations of 354165000.0 for Q1 2026, down 82.15% year-over-year from 1984211836.19 in Q1 2025, and down 29.15% quarter-over-quarter from 274238000.0 in Q4 2025.
Revolution Medicines (RVMDW) Cash from Operations (2019 - 2026) Analysis & Trends
Revolution Medicines' Cash from Operations history runs 8 years deep, the most recent figure standing at 354165000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 82.15% year-over-year to 354165000.0; the TTM figure through Mar 2026 stood at 1057471000.0 (down 78.83% YoY), while the FY2025 annual figure was 897741000.0, down 61.05% from the prior year.
- Cash from Operations for Q1 2026 stood at 354165000.0, down from 274238000.0 in the prior quarter.
- The five-year high for Cash from Operations was 51737000.0 in Q3 2022, with the low at 354165000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 128167000.0 (2024), against an average of 140253823.53.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations declined 13.11% in 2023, then sank 157.34% in 2024.
- Revolution Medicines' Cash from Operations stood at 61788000.0 in 2022, then slumped by 95.12% to 120563000.0 in 2023, then dropped by 14.7% to 138290000.0 in 2024, then tumbled by 98.31% to 274238000.0 in 2025, then dropped by 29.15% to 354165000.0 in 2026.
- Business Quant data shows RVMDW's Cash from Operations at 354165000.0 in Q1 2026, 274238000.0 in Q4 2025, and 207311000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Revolution Medicines | 2.45 Bn | 2.45 Bn | - | -387.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -387.32 Mn |
| Jun 30, 2026 | -387.32 Mn |
| Mar 31, 2026 | -354.17 Mn |
| Mar 31, 2026 | -354.17 Mn |
| Dec 31, 2025 | -274.24 Mn |
| Dec 31, 2025 | -274.24 Mn |
| Sep 30, 2025 | -207.31 Mn |
| Sep 30, 2025 | -207.31 Mn |
| Jun 30, 2025 | -221.76 Mn |
| Jun 30, 2025 | -221.76 Mn |
| Mar 31, 2025 | -194.44 Mn |
| Mar 31, 2025 | -194.44 Mn |
| Dec 31, 2024 | -138.29 Mn |
| Dec 31, 2024 | -138.29 Mn |
| Sep 30, 2024 | -130.42 Mn |
| Sep 30, 2024 | -130.42 Mn |
| Jun 30, 2024 | -128.17 Mn |
| Jun 30, 2024 | -128.17 Mn |
| Mar 31, 2024 | -160.56 Mn |
| Mar 31, 2024 | -160.56 Mn |